TriStrata Accuses ICN of Infringing Patents

ICN Pharmaceuticals Inc., maker of the hepatitis drug ribavirin, was accused in a lawsuit by rival TriStrata Technology Inc. of infringing patents for wrinkle treatments.

TriStrata, a unit of closely held Princeton, N.J.-based NeoStrata Co., claims that ICN is wrongly using its alpha hydroxy acid skin-care inventions.

ICN sells products including the Gly Derm line that infringe five TriStrata-owned patents awarded since 1992, according to the federal court lawsuit filed Monday in Wilmington, Del.

ICN did not comment on the suit.